Stockreport

Hims & Hers stock rises 14% as FDA schedules peptide compounding review [Yahoo! Finance]

Hims & Hers Health, Inc. Class A  (HIMS) 
PDF Hims & Hers Health stock rose 13.7%, with premarket trading adding another 9.6% the next morning, MarketWatch reported. The FDA peptide review will cover BPC-157, KPV, T [Read more]